03:53 PM EST, 12/10/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Tuesday that results from the ongoing phase 2 Evangeline trial showed that (Z)-endoxifen achieved target tissue concentrations and demonstrated substantial tumor suppression in premenopausal women with a type of breast cancer.

The drug candidate was generally well tolerated with manageable side effects, according to the company.

Based on findings from the pharmacokinetic run-in phase, the company plans to proceed with an amended protocol comparing (Z)-endoxifen 40 milligrams per day with ovarian function suppression to exemestane plus OFS.

Recruitment for this cohort will start in 2025, the company added.